Evidence map›Paper›PMID 29025582›Full record

ArticleCancer genetics2017

A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia.

Alfred Chung, Yanli Hou, Robert S Ohgami, Ann Von Gehr, Dianna G Fisk, Krishna M Roskin, Xu Li, Linda Gojenola, Charles D Bangs, Daniel A Arber and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 20 citations in OpenAlex.

  1. ACold Spring Harbor molecular case studies · 2023
    Review
  2. Article
  3. Myeloid/lymphoid neoplasms with FLT3 rearrangement.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Article
  4. Two myeloid leukemia cases with rareCold Spring Harbor molecular case studies · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Alfred ChungDepartment of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Yanli HouDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Robert S OhgamiDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Ann Von GehrKaiser Permanente, San Jose Medical Group, San Jose, CA 95119, USA.
Dianna G FiskDepartment of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.
Krishna M RoskinDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Xu LiKaiser Permanente, San Jose Medical Group, San Jose, CA 95119, USA.
Linda GojenolaMolecular Genetic Pathology Service, Stanford Health Care, Stanford, CA 94305, USA.
Charles D BangsCytogenetics Laboratory, Stanford Health Care, Stanford, CA 94305, USA.
Daniel A ArberDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Andrew Z FireDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Athena M CherryDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.
James L ZehnderDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Hematology, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA, USA.
Jason GotlibDivision of Hematology, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA, USA.
Jason D MerkerDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: jason.gotlib@stanford.edu.
Stanford University · USKaiser Permanente San Jose Medical Center · USStanford Cancer InstituteStanford Health Care · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Melinda L. Telli · 2007 to 2026
$71.4M
NCI NIH HHS P30 CA124435
6 · The paper itself

Abstract

FLT3 fusions are associated with myeloid and lymphoid neoplasms with eosinophilia. We describe a patient presenting with clinicopathologic features of both chronic eosinophilic leukemia, not otherwise specified (CEL, NOS) and systemic mastocytosis (SM). The bone marrow demonstrated a myeloproliferative neoplasm with eosinophilia and aggregates of atypical mast cells. Cytogenetic analysis revealed a t(13;14)(q12;q32), which was subsequently molecularly characterized as a novel TRIP11-FLT3 rearrangement. A KIT D816V mutation was also identified. The patient rapidly transformed to T-lymphoblastic leukemia/lymphoma and expired shortly after diagnosis. This is the fifth FLT3 fusion gene described in the literature; the presence of both myeloid and lymphoid neoplasms implicates involvement of an early hematopoietic progenitor by rearranged FLT3. We suggest that leukemias and lymphomas with FLT3 fusion genes exhibit similar clinicopathologic features to, and should be included in, the WHO category of "Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2."

Indexed as

AdultAgedEosinophiliaFemalefms-Like Tyrosine Kinase 3HumansLymphomaMaleMiddle AgedMyeloproliferative DisordersOncogene Proteins, Fusionfms-Like Tyrosine Kinase 3Oncogene Proteins, FusionTRIP11-FLT3 fusion protein, humanACVRL1 1039G>CACVRL1 Ala347ProFLT3 rearrangementKIT D816VTRIP11

Identifiers

PMID29025582
PMCPMC12396770
OpenAlexW2613869149

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.